Veeva Systems Inc. $VEEV Shares Sold by Cetera Investment Advisers

Cetera Investment Advisers lowered its stake in Veeva Systems Inc. (NYSE:VEEV) by 1.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 76,126 shares of the technology company’s stock after selling 1,244 shares during the period. Cetera Investment Advisers’ holdings in Veeva Systems were worth $21,923,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. increased its position in shares of Veeva Systems by 2.2% in the 1st quarter. Vanguard Group Inc. now owns 14,760,566 shares of the technology company’s stock valued at $3,418,990,000 after acquiring an additional 315,421 shares during the period. Alliancebernstein L.P. grew its stake in Veeva Systems by 10.7% during the 1st quarter. Alliancebernstein L.P. now owns 5,499,651 shares of the technology company’s stock valued at $1,273,884,000 after purchasing an additional 532,269 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its holdings in shares of Veeva Systems by 0.7% in the first quarter. T. Rowe Price Investment Management Inc. now owns 5,203,867 shares of the technology company’s stock valued at $1,205,372,000 after purchasing an additional 34,169 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in shares of Veeva Systems by 20.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,992,372 shares of the technology company’s stock valued at $924,754,000 after purchasing an additional 689,700 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in shares of Veeva Systems by 7.5% in the first quarter. JPMorgan Chase & Co. now owns 3,230,758 shares of the technology company’s stock worth $748,341,000 after purchasing an additional 225,125 shares during the last quarter. 88.20% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Veeva Systems news, SVP Jonathan Faddis sold 720 shares of the company’s stock in a transaction on Monday, October 6th. The stock was sold at an average price of $298.12, for a total value of $214,646.40. Following the completion of the sale, the senior vice president directly owned 7,868 shares in the company, valued at $2,345,608.16. This represents a 8.38% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Thomas D. Schwenger sold 3,350 shares of the firm’s stock in a transaction dated Thursday, October 2nd. The stock was sold at an average price of $300.04, for a total transaction of $1,005,134.00. Following the sale, the insider owned 23,773 shares of the company’s stock, valued at approximately $7,132,850.92. The trade was a 12.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 24,665 shares of company stock worth $7,438,000 over the last ninety days. Corporate insiders own 10.30% of the company’s stock.

Analyst Ratings Changes

VEEV has been the topic of a number of recent research reports. Piper Sandler increased their price target on shares of Veeva Systems from $325.00 to $355.00 and gave the stock an “overweight” rating in a report on Thursday, August 28th. Canaccord Genuity Group upped their price objective on shares of Veeva Systems from $270.00 to $300.00 and gave the company a “hold” rating in a report on Thursday, August 28th. BMO Capital Markets assumed coverage on shares of Veeva Systems in a research note on Thursday, November 13th. They issued a “market perform” rating and a $300.00 price objective on the stock. Stifel Nicolaus boosted their target price on shares of Veeva Systems from $295.00 to $320.00 and gave the company a “buy” rating in a research report on Thursday, August 28th. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $325.00 price target on shares of Veeva Systems in a report on Thursday, August 28th. Seventeen investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $307.28.

Veeva Systems Price Performance

Shares of NYSE:VEEV opened at $273.82 on Wednesday. The business’s 50 day moving average price is $288.61 and its 200-day moving average price is $278.56. Veeva Systems Inc. has a 1 year low of $201.54 and a 1 year high of $310.50. The firm has a market capitalization of $44.88 billion, a price-to-earnings ratio of 56.23, a price-to-earnings-growth ratio of 2.22 and a beta of 0.98.

Veeva Systems (NYSE:VEEV) last released its quarterly earnings results on Wednesday, August 27th. The technology company reported $1.26 earnings per share for the quarter, missing the consensus estimate of $1.90 by ($0.64). The company had revenue of $789.08 million for the quarter, compared to analyst estimates of $768.49 million. Veeva Systems had a return on equity of 13.72% and a net margin of 27.29%.The firm’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same quarter last year, the company earned $1.62 EPS. Veeva Systems has set its Q3 2026 guidance at 1.940-1.950 EPS. FY 2026 guidance at 7.780-7.780 EPS. On average, sell-side analysts expect that Veeva Systems Inc. will post 4.35 earnings per share for the current year.

Veeva Systems Company Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.